Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19799
Title: Management of bone and metabolic effects of androgen deprivation therapy.
Austin Authors: Russell, Nicholas ;Grossmann, Mathis 
Affiliation: Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 2021
metadata.dc.date: 2018-11-13
Publication information: Urologic oncology 2021; 39(10): 704-712
Abstract: Androgen deprivation therapy (ADT) is commonly given to men with prostate cancer. Both its benefits as well as its adverse effects are a direct consequence of sex steroid withdrawal. While ADT improves oncologic outcomes in appropriately selected men, it is associated with adverse effects, including accelerated bone loss leading to increased fracture risk, and with metabolically unfavorable body composition changes that predispose to diabetes and may increase cardiovascular risk. In this review, we will describe the pathophysiology behind these ADT-associated adverse effects, and discuss the clinical evidence guiding clinical assessment and management. A proactive approach is important to minimize ADT-associated adverse sequelae, so that the benefit-risk ratio of this treatment is optimized.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19799
DOI: 10.1016/j.urolonc.2018.10.007
ORCID: 0000-0001-8261-3457
PubMed URL: 30446463
Type: Journal Article
Subjects: 25(OH)D
25-hydroxy vitamin D
ADT
AR
ARKO
Androgen deprivation therapy
BMD
BP
CRPC
CaP
DBP
DXA
Diabetes
GnRH
HDL-C
HR-PQCT
LBM
LDL-C
Osteoporosis
Prostate cancer
RCT
SBP
TC
TG
androgen deprivation therapy
androgen receptor
androgen receptor knockout
blood pressure
bone mineral density
castrate-resistant Prostate cancer
diastolic blood pressure
dual energy X-ray absorptiometry
gonadotrophin-releasing hormone
high density lipoprotein cholesterol
high resolution-peripheral quantitative computed tomography
lean body mass
low density lipoprotein cholesterol
Prostate cancer
randomized controlled trial
systolic blood pressure
total cholesterol
triglycerides
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Dec 7, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.